JPWO2024111552A1 - - Google Patents

Info

Publication number
JPWO2024111552A1
JPWO2024111552A1 JP2024560142A JP2024560142A JPWO2024111552A1 JP WO2024111552 A1 JPWO2024111552 A1 JP WO2024111552A1 JP 2024560142 A JP2024560142 A JP 2024560142A JP 2024560142 A JP2024560142 A JP 2024560142A JP WO2024111552 A1 JPWO2024111552 A1 JP WO2024111552A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560142A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2024111552A1 publication Critical patent/JPWO2024111552A1/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024560142A 2022-11-21 2023-11-20 Pending JPWO2024111552A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022185858 2022-11-21
PCT/JP2023/041643 WO2024111552A1 (ja) 2022-11-21 2023-11-20 経口固形製剤

Publications (1)

Publication Number Publication Date
JPWO2024111552A1 true JPWO2024111552A1 (https=) 2024-05-30

Family

ID=91195626

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560142A Pending JPWO2024111552A1 (https=) 2022-11-21 2023-11-20

Country Status (4)

Country Link
EP (1) EP4623916A1 (https=)
JP (1) JPWO2024111552A1 (https=)
CN (1) CN120225199A (https=)
WO (1) WO2024111552A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002179571A (ja) * 2000-12-11 2002-06-26 Nikken Chem Co Ltd 小型徐放性錠剤
CA2443632C (en) * 2001-04-10 2011-05-03 Sun Pharmaceutical Industries Limited Timed pulse release composition
WO2002087549A1 (fr) * 2001-04-25 2002-11-07 Taisho Pharmaceutical Co., Ltd. Comprimes a liberation prolongee du type a unites multiples
JP5524624B2 (ja) * 2007-11-16 2014-06-18 旭化成ケミカルズ株式会社 水系フィルムコーティング液、および、フィルムコーティング顆粒、ならびに、これを用いた錠剤
JP6186139B2 (ja) * 2013-03-08 2017-08-23 杏林製薬株式会社 口腔内速崩壊性錠剤
JP2017222645A (ja) * 2016-06-10 2017-12-21 大原薬品工業株式会社 腸溶性被覆顆粒の耐酸性が改善された圧縮成形錠剤
KR101907116B1 (ko) * 2016-07-25 2018-10-11 한미약품 주식회사 에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
ES2992887T3 (en) 2017-04-27 2024-12-19 Mochida Pharm Co Ltd Novel tetrahydronaphthyl urea derivatives as inhibitors of tropomyosin receptor kinase a for the treatment of pain
JP7009288B2 (ja) * 2017-05-18 2022-01-25 エルメッド株式会社 湿製錠剤の製造方法及び湿製錠剤の品質向上方法
WO2019189717A1 (ja) 2018-03-30 2019-10-03 持田製薬株式会社 テトラヒドロナフチルウレア誘導体の製造方法

Also Published As

Publication number Publication date
EP4623916A1 (en) 2025-10-01
CN120225199A (zh) 2025-06-27
WO2024111552A1 (ja) 2024-05-30

Similar Documents

Publication Publication Date Title
JPWO2024111552A1 (https=)
BR102022023461A2 (https=)
BR102022017795A2 (https=)
CN307047065S (https=)
BY13136U (https=)
BY13139U (https=)
CN307049180S (https=)
CN307048593S (https=)
CN307048413S (https=)
CN307047635S (https=)
BY13140U (https=)
CN307047571S (https=)
CN307047406S (https=)
CN307047333S (https=)
CN307046923S (https=)
CN307045796S (https=)
CN307045535S (https=)
CN307045145S (https=)
CN307044712S (https=)
CN307044525S (https=)
CN307044399S (https=)
CN307044398S (https=)
BY13168U (https=)
BY13166U (https=)
BY13165U (https=)